title: Methamphetamine-induced sensitization of dopamine release via a metabotropic glutamate receptor mediated pathway in rat striatal slices.
abstract: We studied the roles of metabotropic glutamate receptors in methamphetamine (MAP)-induced sensitization of dopamine (DA) release from striatal slices. Rats were first treated with MAP (1 mg/kg, i.p.) once daily for 6 consecutive days. After a 6-day withdrawal, DA release from striatal slices evoked by +/- (-)1-aminocyclopentane-trans-1,3-dicarboxylic acid (trans-ACPD) was measured, trans-ACPD-induced DA release was significantly enhanced in MAP-sensitized rats, but the inactive form of trans-ACPD (1R,3S-ACPD) did not enhance DA release. The active form of trans-ACPD (1S,3R-ACPD) (0.1 mM)-evoked DA release was attenuated by treatment with 0.4 mM RS-alpha-methyl-4-carboxyphenylglycine, a metabotropic glutamate receptor antagonist. The present results suggest that metabotropic glutamate receptors play an important role in expression of MAP-induced sensitization.
authors.affiliation: Department of Pharmacology, Faculty of Pharmaceutical Sciences, Kyushu University 62, Fukuoka, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Arai
authors.forename: T
authors.initials: T
authors.lastname: Shimazoe
authors.forename: S
authors.initials: S
authors.lastname: Shibata
authors.forename: H
authors.initials: H
authors.lastname: Inoue
authors.forename: A
authors.initials: A
authors.lastname: Yoshimatsu
authors.forename: S
authors.initials: S
authors.lastname: Watanabe
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001565:Benzoates / Q000008:administration & dosage / Q000633:toxicity; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D003515:Cycloleucine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D018765:Dopamine Uptake Inhibitors / Q000633:toxicity*; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000633:toxicity; D005998:Glycine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000633:toxicity; D007274:Injections, Intraperitoneal; D008297:Male; D008694:Methamphetamine / Q000633:toxicity*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists* / Q000037:antagonists & inhibitors; D013237:Stereoisomerism
chemical_list: D001565:Benzoates; D018765:Dopamine Uptake Inhibitors; D018691:Excitatory Amino Acid Antagonists; D018696:Neuroprotective Agents; D018094:Receptors, Metabotropic Glutamate; D003515:Cycloleucine; C036361:1-amino-1,3-dicarboxycyclopentane; C079694:alpha-methyl-4-carboxyphenylglycine; D008694:Methamphetamine; D005998:Glycine; D004298:Dopamine